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Follow up was with CXR at 6months followed by CT at 6 
months and clinical follow up, 3 monthly. 
 
Results: 167 patients with stage IA-IIB disease treated. 55% 
histologically proven.There were 4 (2.4%) radiologically 
confirmed local recurrences giving a local control rate of 
97.6%. Median survival was 43.2months. 3 year Overall 
Survival was 56.4% (see Fig 1). Treatment was well tolerated 
with minimal G3 toxicity (5 patients). 
 
Conclusion: Our results suggest that SABR for medically 
inoperable NSCLC can be safely and effectively implemented 
in a non-academic institution with appropriate equipment 
and training.Clinical outcomes are comparable with 
internationally published series [3}, with encouraging 3yr OS 
rate of 56%. Toxicity is minimal. Longer term follow-up is 
required to confirm findings and provide data regarding long-
term toxicity. 
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Purpose or Objective: In patients with inoperable stage I 
non-small cell lung cancer (NSCLC) or for those refusing 
surgery, stereotactic body radiotherapy and particle 
radiotherapy have become therapeutic options. We 
conducted a Phase I/II study on single-fraction carbon ion 
radiotherapy (SF-CIRT) for stage I NSCLC that yielded a 3-year 
survival rate of 75.5% for 218 patients. Until now, the effect 
of hypofractionated CIRT on pulmonary function (PF) has not 
been well documented. The purpose of this study was to 
assess the long-term impact of SF-CIRT on PF in stage I NSCLC 
patients. 
 
Material and Methods: A review of prospectively collected 
data from SF-CIRT-treated patients was performed. Patients 
underwent PF tests (PFT) (or: underwent a PF test) 
immediately before, and at 6, 12, and 24 months after 
irradiation. Patients who relapsed or needed adjuvant 
treatment were excluded as these events might affect PF.  
 
Results:  
 
 
Forty patients treated between 2007 and 2012 fulfilled the 
inclusion criteria. According to the dose escalation study 
protocol, a median prescribed single-fraction dose of 46 GyE 
(range, 44-50 GyE) was delivered. All treatment-related 
complications were self-limited, without any grade 3-5 
toxicities. Two years post-CIRT, the mean values of forced 
expiratory volume in 1 sec (FEV1) [-8.4% ± 11.9% (p < 0.001)] 
and the FEV1 per unit of forced vital capacity (FEV1/FVC) [-
8.9% ± 11.7% (p < 0.001)] were less than the pre-CIRT values. 
There were no significant overall changes in total lung 
capacity, vital capacity, FVC, and residual volume before SF-
CIRT and 2 years after SF-CIRT. At 6 months post-treatment, 
the diffusion capacity of the lung for carbon monoxide 
(DLCO) was significantly less than the pretreatment value 
(86.7 ± 32.7% vs. 78.1 ± 31.1%; p = 0.002); however, at 24 
months post-treatment, the mean DLCO recovered to 
pretreatment levels (86.9 ± 30.5%). This might have been due 
to recovery from non-symptomatic radiation pneumonitis 
and/or smoking cessation. 
 
 
 
Conclusion: We found stage I NSCLC patients had good long-
term preservation of PF after SF-CIRT. Follow-up PFT 
revealed the following: Declines in FEV1 and FEV1/FVC were 
statistically significant but clinically trivial, DLCO decreased 
temporary, thereafter it tended to recover to pretreatment 
levels within 2 years. 
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Purpose or Objective: An evaluation of thymic tumors 
patient radiotherapy results.  
 
Material and Methods: 93 patients (54F [58%], 39M [42%]) 
aged from 3 (6 children) to 77 (median 48) treated for thymic 
tumors since 1981. 84 patients (90%) were diagnosed with 
thymoma, 9 (10%) with thymic carcinoma. Masaoka stage was 
assessed in 93% (56% stage II, 31%-III, 6%- IV). All patients 
were irradiated. In 76 cases radiotherapy (RT) followed 
surgery – in 41 patients after radical and in 35 after 
incomplete resection. In 17 cases RT was definitive 
treatment, combined in 14 patients with chemotherapy. 
Patients were irradiated with fraction dose of 1.1-4.0Gy 
(median 2.0) to the total dose of 20-68Gy (median 49.5). 
Patient- and treatment-related factors potentially affecting 
survival and local control (LC) were evaluated with log-rank 
test. Survival analysis was performed with Kaplan-Meier 
method. 
 
Results: Tumors relapsed in 17 patients. Metastases occurred 
after 6-129months (median 10.1) in 12 patients (in 8 in 
lungs). During the follow-up 17 patients died due to 
progression(13) or recurrence(4) of the disease. Median 
overall survival (OS) in the whole group (since diagnosis) was 
140.2months. OS was significantly longer in patients with 
WHO B1 type(p=0.02), in good performance status 
(PS)(p=0.0005), without radiation-induced pulmonary 
fibrosis(p=0.02) or second cancer(p=0.03). Difference in OS 
between patients treated with radical surgery+RT, non-
radical surgery+RT and definitive RT was of borderline 
significance(p=0.065). Factors significantly decreasing LC 
were: male sex(p=0.04), WHO B2 type(p=0.01), bad 
PS(p=0.0007), presence of metastases(p=0.003) and second 
cancer(p=0.03).  
 
S576                                                                                                                                                  ESTRO 35 2016 
_____________________________________________________________________________________________________ 
Conclusion: Obtained results do not permit to form robust 
conclusion concerning role of RT in the management of 
thymic tumors patient. Besides clear, unquestionable bad 
prognostic factors as bad PS, low differentiation, presence of 
local relapse, lung fibrosis, second malignancy or distant 
metastases, we found only one more - male sex, decreasing 
LC. 
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Purpose or Objective: In a UK Medical Research Council trial 
carried out before the widespread use of chemotherapy or 
CT-PET, palliative thoracic radiotherapy delivering 39 Gy in 
13 daily fractions conferred an overall survival (OS) benefit 
when compared to 17 Gy in 2 weekly fractions in good 
performance status patients with radically treatable NSCLC. 
To determine whether this benefit persisted with 
contemporary standards of staging and systemic therapy, we 
studied the outcomes of patients with locally 
advanced/metastatic NSCLC receiving palliative radiotherapy 
in our centre over a 2 year period. 
 
Material and Methods: The case records of 176 patients who 
received palliative thoracic radiotherapy in 2011 or 2012 
were reviewed retrospectively. Data collected included age, 
stage, performance status, dose/fractionation, additional 
treatments and survival. 
 
Results: 36 patients received high dose thoracic radiotherapy 
(HDTRT, 36-40 Gy in 12-15 fractions) and 140 received a 
lower dose (LDTRT), 20 Gy in 5 fractions. Median OS in the 
HDTRT group was 8.5 months and 5.5 months in the LDTRT 
group (hazard ratio 0.6, p <0.01). 12 patients received 
chemotherapy and HDTRT with median OS 12m vs 7m in the 
25 patients receiving chemotherapy and LDTRT. In those who 
received HDTRT alone, median OS was 6.5m vs 4m for LDTRT 
alone. In patients with stage II-III disease median OS was 
9.6m vs 6m for LDTRT. In those with stage IV disease, median 
OS was 8m for HDTRT vs 5m for LDTRT. In patients with 
performance status 0-2 median OS was 9m for HDTRT vs 6m 
for LDTRT, while in the two patients with performance status 
3 who were irradiated it was 1m with HDTRT vs 3m with 
LDTRT. 
 
Conclusion: This audit of contemporary practice suggests 
that the survival benefit of high dose palliative radiotherapy 
reported by Macbeth (Clin Oncol (R Coll Radiol). 1996;8:167-
75) persists with modern staging and systemic therapy 
practices, and may also extend to patients with small volume 
stage IV disease excluded from that trial, but not those with 
poor performance status. 
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Purpose or Objective: SBRT is the standard treatment of 
early stage inoperable NSCLC. Parenchymal changes (PC) 
after SBRT make it difficult the differential diagnosis 
between treatment effects and disease recurrence. The 
purpose of our study was to identify the radiographic 
features (High Risk Features: HRFS) with high specificity (SP) 
and sensitivity (SE) for early detection of recurrence. 
 
Material and Methods: We retrospectively evaluated patients 
treated with SBRT for inoperable early stage NSCLC. Median 
dose was 50 Gy in 5 fractions (range, 45-60 Gy /3-12 
fractions) prescribed to 80% isodose. All patients underwent 
chest computed tomography (CT) before SBRT and after 3, 6, 
12 months (thereafter annually). Using a chest CT scan 
radiological aspects according to Huang et al. classification 
(Huang et al., Radiother Oncol 2013;109:51-57) were 
evaluated. 18F FDG-PET was used in case of suspected tumor 
recurrence. 
 
Results: Forty-five patients were included, 34 males and 11 
females; mean age was 75.7 years (range, 60-86 years); 
77.8% of patients had stage IA disease and 22.2% stage IB 
with a mean follow-up of 21 months, local control was 69%. 
Benign acute CT changes (up to 6 months after SBRT) were 
observed in 34 patients (patchy consolidation was the most 
frequent) and late changes (after 6 months) in 44 patients 
(mass-like fibrosis was the most frequent). HRFs were 
identified in 20 patients, enlarging opacity at primary site in 
9 patients, enlargement after 12 months in 20 patients, 
bulging margin in 7 patients, disappearance of linear margin 
in 2 patients, loss of air bronchogram in 18 patients and 
cranial-caudal growth in 15 patients. These HRFs were 
individually significantly associated with local recurrence of 
the disease. The better predictor of relapse was enlargement 
opacity at 12 months (p <0.001) with SE: 84.6% and SP: 
71.8%. The presence of > 1 HRFS demonstrated a higher SE 
(93.3%) (p <0.02) with SP: 59.4%. 
 
Conclusion: Detection of HRFS is predictive of relapse with a 
SE increasing with the number of observed HRFs. This 
observation allows to better define the diagnostic algorithm 
in follow-up, suggesting to perform further exams only in 
patients with > 1 HRFS. 
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Purpose or Objective: Because there is a positive correlation 
between radiation dose and local control (LC) in non-small 
cell lung cancer (NSCLC) although with no impact on overall 
survival (OS) our institutional protocol allowed moderate 
radiotherapy dose escalation up to 70 - 74 Gy (BED: 84 - 88.8 
Gy) on the standard 60-66 Gy (BED: 72 - 79.2 Gy) providing 
that organs-at-risk are keep in tolerance. This retrospective 
study aims to assess the impact of dose escalation in clinical 
outcome when the duration of radiotherapy is taken in to 
account through the use of BED model corrected by time 
(tBED) 
 
Material and Methods: 78 consecutively patients with 
unresectable NSCLC were retrospectively analyzed. All were 
PET-CT staged and were treated with platinum-based 
chemotherapy (either concomitant or sequential) and 3DCRT. 
Two groups were compared according to prescribed dose 
level: Standard Dose Group (SD) n = 38 those receiving 
nominal prescribed BED ≤ 79.2 Gy and Escalated Dose Group 
(ED) n = 40 those receiving > nominal prescribed BED >79.2 
Gy. For both groups actual administered dose corrected for 
the duration of treatment (tBED) was calculated using the 
formula [tBED (Gy) = n d (1+d/ α/β) – KT] (Sinclair, IJROBP 
1999. 44:381) Multivariate Cox regression analysis was 
performed to identify significant predictors of OS, Disease 
Free Survival (DFS) and Thoracic Progression Free Survival 
(TPFS). For purposes of comparison a nominal prescribed 
dose of 60 Gy @2Gy in 39 days have a tBED = 44, 7 Gy. 
 
